STOCK TITAN

SPRCY - $SPRCY STOCK NEWS

Welcome to our dedicated page for SPRCY news (Ticker: $SPRCY), a resource for investors and traders seeking the latest updates and insights on SPRCY stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SPRCY's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SPRCY's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.48%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.13%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
SPRCY

OTC:SPRCY

SPRCY Rankings

SPRCY Stock Data

0
Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About SPRCY

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Its focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy.